Adalimumab biosimilar - Merck & Co./Samsung Bioepis

Alternative Names: Imraldi; SB-5

Latest Information Update: 10 Apr 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Samsung Bioepis
Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis

Most Recent Events

05 Apr 2018 Samsung Bioepis and AbbVie signed licensing agreement to settle patent dispute
05 Apr 2018 Samsung Bioepis expects to launch adalimumab biosimilar in Europe in fourth quarter of 2018
05 Apr 2018 Samsung Bioepis expects to launch adalimumab biosimilar in USA in second quarter of 2023

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.